Evidence map›Paper›PMID 27374491›Full record

ReviewActa pharmacologica Sinica2016

Anticancer strategies based on the metabolic profile of tumor cells: therapeutic targeting of the Warburg effect.

Xi-Sha Chen, Lan-Ya Li, Yi-di Guan, Jin-Ming Yang, Yan Cheng

Open access · bronzeAbstract readReview
In one paragraph

Review in Acta pharmacologica Sinica, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 123 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Hypoxia Imaging as a Radiomics Signature in Tumors Using NovelbioRxiv : the preprint server for biology · 2025
    Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. The role of acetylation and deacetylation in cancer metabolism.Clinical and translational medicine · 2025
    Review
  16. Targeting the Warburg Effect in Cancer: Where Do We Stand?International journal of molecular sciences · 2024
    Review
  17. Review
  18. The novel family of WarbicinFrontiers in oncology · 2024
    Article
  19. Article
  20. Article

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Xi-Sha ChenDepartment of Pharmacology, School of Pharmaceutical Sciences, Central South University, Changsha 410008, China.
Lan-Ya LiDepartment of Pharmacology, School of Pharmaceutical Sciences, Central South University, Changsha 410008, China.
Yi-di GuanDepartment of Pharmacology, School of Pharmaceutical Sciences, Central South University, Changsha 410008, China.
Jin-Ming YangDepartment of Pharmacology, the Penn State Hershey Cancer Institute, the Pennsylvania State University College of Medicine and Milton S Hershey Medical Center, Hershey, PA 17033, USA.
Yan ChengDepartment of Pharmacology, School of Pharmaceutical Sciences, Central South University, Changsha 410008, China.
Central South University · CNPenn State Milton S. Hershey Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor cells rely mainly on glycolysis for energy production even in the presence of sufficient oxygen, a phenomenon termed the Warburg effect, which is the most outstanding characteristic of energy metabolism in cancer cells. This metabolic adaptation is believed to be critical for tumor cell growth and proliferation, and a number of onco-proteins and tumor suppressors, including the PI3K/Akt/mTOR signaling pathway, Myc, hypoxia-inducible factor and p53, are involved in the regulation of this metabolic adaptation. Moreover, glycolytic cancer cells are often invasive and impervious to therapeutic intervention. Thus, altered energy metabolism is now appreciated as a hallmark of cancer and a promising target for cancer treatment. A better understanding of the biology and the regulatory mechanisms of aerobic glycolysis has the potential to facilitate the development of glycolysis-based therapeutic interventions for cancer. In addition, glycolysis inhibition combined with DNA damaging drugs or chemotherapeutic agents may be effective anticancer strategies through weakening cell damage repair capacity and enhancing drug cytotoxicity.

Indexed as

Antineoplastic AgentsGlycolysisHumansModels, MolecularNeoplasmsAntineoplastic Agents

Identifiers

PMID27374491
PMCPMC4973382
OpenAlexW2470315552

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.